Skip to main content

Table 3 Dose modification protocol according to the level of adverse reaction caused by capecitabine therapy (Toxicity according to NCI CTC Version 3.0)

From: A prospective, non-randomized phase II trial of Trastuzumab and Capecitabine in patients with HER2 expressing metastasized pancreatic cancer

Toxicity

occurrence

suggested measure

dose during following cycle (% of original dose)

1

 

continue with current dose

100%

2

1st occurrence

discontinue treatment till restitution to grade 0 or 1 toxicity

100%

 

2nd occurrence

discontinue treatment till restitution to grade 0 or 1 toxicity

75%

 

3rd occurrence

discontinue treatment till restitution to grade 0 or 1 toxicity

50%

 

4th occurrence

final discontinuation of treatment

-

3

1st occurrence

discontinue treatment till restitution to grade 0 or 1 toxicity

75%

 

2nd occurrence

discontinue treatment till restitution to grade 0 or 1 toxicity

50%

 

3rd occurrence

final discontinuation of treatment

-

4

1st occurrence

final discontinuation of treatment or discontinuation till restitution to grade 0 or 1 toxicity

50%